Skip to main content

Clinical trial XL184-313

A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk

Cancers
Organ Multiple
Trial status Trial closed for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Exelixis
EudraCT Identifier 2018-004567-31
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03937219
Inclusion criteria Intermediate or poor risk metastatic clear cell renal cell carcinoma in 1st line treatment.
Last update